H&E stain kit
December 2018—Sakura Finetek USA launched the Tissue-Tek Prisma H&E Stain Kit #1, specifically designed for the Tissue-Tek Prisma line of stainers.
Webinars and Sponsored Roundtables — Register Now
Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
BD launches TB test in Europe
December 2018—BD announced the availability of the CE-marked BD Max MDR-TB panel in Europe. Clinicians can use the single PCR-based molecular diagnostic test to simultaneously detect bacteria that cause tuberculosis and determine if the bacteria contain mutations associated with resistance to two first-line drugs, isoniazid and rifampicin.
FDA grants EUA for Chembio Ebola test
December 2018—Chembio Diagnostics announced FDA emergency use authorization for its DPP Ebola Antigen System for use with human capillary fingerstick whole blood, EDTA venous whole blood, and EDTA plasma. The test detects viral antigens and provides qualitative results in 15 to 20 minutes when used with the handheld, battery-operated DPP Micro Reader.
Body fluids kit
December 2018—LGC Maine Standards has released its Validate Body Fluids kit, 205bf. The kit, in a simulated body fluid matrix, will assist in the documentation of linearity, calibration verification, and verification of the reportable range for albumin, amylase, cholesterol, creatinine, glucose, lactate, lactate dehydrogenase, total protein 2, triglycerides, and urea nitrogen.
Bone marrow engraftment assay
December 2018—Agena Bioscience released its Chimeric ID Panel, designed to reduce the time and cost of performing chimerism analysis for bone marrow engraftment monitoring studies.
QIAamp PowerFecal Pro DNA Kit
December 2018—Qiagen announced the worldwide launch of the QIAamp PowerFecal Pro DNA Kit, for the extraction of high-quality DNA from fecal and gut samples.
Online diagnostic encyclopedia of medicine
December 2018—Knowledge-Quest announced a new virtual textbook titled “Diagnostic Encyclopedia of Medicine,” or DxEM, a digital library for medical diagnosis available at dxconcur.com.
Direct-to-consumer pharmacogenetic reports
December 2018—The FDA has granted 23andMe de novo authorization to offer direct-to-consumer reports on pharmacogenetics. The authorization allows 23andMe to report variants in multiple genes that are associated with how an individual may metabolize some medications.
OncoBeam shows clinical value for melanoma patients
December 2018—Sysmex Inostics announced publication of a study in the Journal of Molecular Oncology (Rowe SP, et al. 2018;12[10]:1661–1672) highlighting the clinical value of blood-based ctDNA mutation testing to complement standard-of-care management of patients with advanced melanoma.
AMH assay kit gets FDA clearance
December 2018—Ansh Labs has received de novo FDA clearance for its MenoCheck picoAMH ELISA.